Vimarsana
Biggest News Aggregation in the World

Page 4 - Impacts Questionnaire News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Impacts Questionnaire. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Impacts Questionnaire Today - Breaking & Trending Today

QUVIVIQ (daridorexant) recommended for approval in Europe as a new treatment for adults with insomnia disorder - Vimarsana News

QUVIVIQ (daridorexant) recommended for approval in Europe as a new treatment for adults with insomnia disorder

Idorsia Ltd (SIX: IDIA) today announced the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), adopted a positive opinion for the use of QUVIVIQ™ (daridorexant) as the first dual orexin receptor antagonist in the European Union (EU) for the t...

Daridorexant Safe, Effective for Insomnia Disorder - Vimarsana News

Daridorexant Safe, Effective for Insomnia Disorder

Daridorexant (50 mg) improves both nighttime symptoms and daytime functioning in people with insomnia disorder.

Daridorexant Safe, Effective for Insomnia Disorder - Vimarsana News

Daridorexant Safe, Effective for Insomnia Disorder

FRIDAY, Feb. 4, 2022 (HealthDay News) -- Daridorexant (50 mg) improves both nighttime symptoms and daytime functioning in people with insomnia disorder, according to a study published in the Feb.

Newly Approved Drug Improves Sleep Onset in Insomnia - Vimarsana News

Newly Approved Drug Improves Sleep Onset in Insomnia

Daridorexant, a newly approved dual orexin receptor antagonist, improves sleep onset in adult patients, new phase 3 data suggest.

Idorsia Releases New Insomnia Drug Data - Vimarsana News

Idorsia Releases New Insomnia Drug Data

The Idorsia insomnia drug, scheduled for release later this year, offers some relief for the millions of Americans living with insomnia.